Roche's Obesity Drug Enicepatide Shows 15.5% Weight Loss in Mid-Stage Diabetes Trial

Swiss pharmaceutical giant Roche announced Tuesday that its experimental obesity treatment, enicepatide, demonstrated significant weight loss and improved blood sugar levels in a mid-stage trial involving patients with type 2 diabetes. The results position Roche to compete in a rapidly growing market dominated by Novo Nordisk and Eli Lilly.

Key Trial Results

The 447-patient study found that participants receiving the highest dose of enicepatide (24 milligrams) achieved the trial's two main goals over 48 weeks. The once-weekly injection works by mimicking the GLP-1 and GIP hormones to suppress appetite and regulate blood sugar.

Key findings from the highest-dose group include:

• Average weight loss of 15.5%.
• Significant reductions in HbA1c, a measure of average blood sugar over time.
• 62% of patients achieved HbA1c levels below 5.7%, bringing their blood sugar into the non-diabetic range.

Safety Profile and Market Context

Ad

Roche reported that the drug's side effects were primarily mild to moderate gastrointestinal issues. Approximately 2% of patients taking enicepatide discontinued the treatment due to side effects, compared with none in the placebo group.

These results follow a separate mid-stage trial reported in June, where enicepatide helped overweight or obese patients without diabetes lose 22.7% of their body weight. As a dual GLP-1/GIP agonist, enicepatide uses a similar mechanism to highly successful treatments like Eli Lilly's Zepbound, signaling intense competition in the metabolic drug space.

Next Steps

Based on these findings, Roche plans to advance enicepatide into late-stage trials. The company stated it intends to initiate pivotal studies for glycemic control and cardiovascular outcomes in the first half of 2027.